A novel arylethynyltriazole acyclonucleoside inhibits proliferation of drug-resistant pancreatic cancer cells

M.H. Wang (1) , Y. Xia (1) , Y.T. Fan (1) , P. Rocchi , F.Q. Qu , J.L. Iovanna , Ling Peng (1)

1 CINaM - Centre Interdisciplinaire de Nanoscience de Marseille

Novel arylethynyltriazole acyclonucleosides were synthesized and assessed for their anticancer activity on drug-resistant pancreatic cancer MiaPaCa-2 cells. One lead compound was found to have much more potent apoptosis-related antiproliferative effects than gemcitabine, the current first-line treatment for pancreatic cancer. Further investigations showed that this active compound did not inhibit DNA synthesis, which means that it does not resemble gemcitabine and may involve a different mechanism of action.

Mots clés: Acyclic nucleosides; Triazole nucleosides; Pancreatic cancer; Anticancer activity; Sonogashira reaction

Domaines: Chimie

M.H. Wang, Y. Xia, Y.T. Fan, P. Rocchi, F.Q. Qu, et al.. A novel arylethynyltriazole acyclonucleoside inhibits proliferation of drug-resistant pancreatic cancer cells. Bioorganic and Medicinal Chemistry Letters, 2010, 20 (20), pp.5979-5983. ⟨10.1016/j.bmcl.2010.08.093⟩. ⟨hal-00566366⟩